Clinical Trial Update: A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199 [Phase 1]

View source ↗

Summary

Phase 1 study to assess the effect of rifampin on the metabolism of ABT-199 (venetoclax) in Non-Hodgkin lymphoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• venetoclax (ABT-199) (venetoclax)

Snippet

Sponsor: AbbVie | Conditions: Non-Hodgkin's Lymphoma | Phase 1 | Status: WITHDRAWN